Trusted Resource for Clinical Trials, Protocols & Progress
Managing Investigator Turnover and Site Closures in Late-Stage Trials: Strategies for Continuity and Compliance How to Handle Investigator Changes and Site Closures in Phase 3 Clinical Trials Why Investigator Turnover and Site Closures Happen in Phase 3 Trials Phase 3 clinical trials often run for 2–5 years, involve hundreds of global sites, and are subject…
Safety Reporting to Regulators in Phase 4: Timelines and Format How to Meet Regulatory Requirements for Safety Reporting in Phase 4 Clinical Trials Introduction As drugs transition from controlled trials to widespread real-world use, the scope of adverse event reporting broadens considerably. In Phase 4 clinical trials, sponsors are expected to comply with stringent global…
Read More “Safety Reporting to Regulators in Phase 4: Timelines and Format” »
How to Create a Risk-Based Monitoring Plan (RBMP) for Phase 3 Trials: A Step-by-Step Guide Step-by-Step Guide to Building a Risk-Based Monitoring Plan in Phase 3 Clinical Trials Why Risk-Based Monitoring Matters in Phase 3 Trials Phase 3 clinical trials are often global, complex, and resource-intensive. Traditional 100% Source Data Verification (SDV) across all sites…
Real-Time Pharmacovigilance Through Social Media Monitoring in Phase 4 Trials Harnessing Social Media for Real-Time Safety Signal Detection in Phase 4 Clinical Trials Introduction Modern pharmacovigilance extends beyond hospitals, registries, and electronic health records. In today’s digital age, patients share experiences in real time through social media platforms, health forums, and online communities. For sponsors…
Read More “Real-Time Pharmacovigilance Through Social Media Monitoring in Phase 4 Trials” »
Vendor Oversight and Performance Metrics in Global Phase 3 Programs: Managing Partners for Trial Success How to Effectively Oversee Vendors and Track Performance in Global Phase 3 Trials Why Vendor Oversight Is Essential in Phase 3 Global Phase 3 trials involve extensive outsourcing—spanning CROs, central labs, imaging vendors, IRT systems, ePRO providers, and data management…
Leveraging Electronic Health Records and Claims Data in Phase 4 Clinical Trials How to Use EHR and Claims Data to Power Real-World Phase 4 Clinical Research Introduction Phase 4 clinical trials are designed to evaluate a drug’s performance in real-world populations over extended periods. With the rise of digital health systems, researchers can now tap…
Read More “Leveraging Electronic Health Records and Claims Data in Phase 4 Clinical Trials” »
Centralized vs. Decentralized Monitoring Models in Phase 3 Trials: Choosing the Right Oversight Strategy Understanding Centralized and Decentralized Monitoring in Global Phase 3 Clinical Trials Why Monitoring Models Matter in Phase 3 Phase 3 trials involve hundreds of sites, large participant pools, and multi-year timelines—making clinical monitoring one of the most critical aspects of trial…
Label Expansion and New Indications via Phase 4 Studies Using Phase 4 Clinical Trials to Support Label Expansion and New Therapeutic Indications Introduction Phase 4 clinical trials are not only about long-term safety—they’re also powerful tools for label expansion. After a drug receives initial marketing approval, it can be evaluated for use in additional patient…
Read More “Label Expansion and New Indications via Phase 4 Studies” »
Data Integrity and Traceability in Long-Duration Phase 3 Studies: Building Trust Through Robust Data Management How to Maintain Data Integrity and Traceability in Long-Term Phase 3 Clinical Trials Why Data Integrity Matters in Long-Duration Phase 3 Trials Phase 3 clinical trials, especially those involving chronic conditions or long-term treatment outcomes, can span several years. Over…
Incorporating PROs and QoL Data in Phase 4 Clinical Trials How to Integrate Patient-Reported Outcomes and Quality of Life Measures in Phase 4 Studies Introduction Phase 4 clinical trials are increasingly focused on more than just safety and efficacy. Regulatory bodies, payers, and patients now seek a fuller picture of treatment impact. This includes the…
Read More “Incorporating PROs and QoL Data in Phase 4 Clinical Trials” »
